Zaynich is a novel intravenous compound antibacterial agent. Precisely grasping its indications and key precautions during administration is the core of ensuring efficacy and safety. Rational use not only helps control infections but also effectively delays the development of bacterial resistance.
I. Clear Indications and Antibacterial Spectrum
1. Approved Indications
(1) Zaynich is indicated for the treatment of complicated urinary tract infections (cUTI) in adult patients, including pyelonephritis.
(2) This drug should only be used for infections confirmed or highly suspected to be caused by susceptible bacteria, and is not applicable to viral infections.
2. Covered Pathogen Types
(1) It has clinical activity against the following Gram-negative bacteria: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter cloacae complex, and Pseudomonas aeruginosa.
(2) In vitro studies show activity against various beta-lactamase-producing strains (including carbapenemase-producing strains).
3. Rational Use to Delay Resistance
(1) In the absence of bacterial culture and susceptibility results, empirical therapy may be guided by local epidemiology and resistance trends.
(2) Once susceptibility data are available, the treatment regimen should be promptly evaluated and adjusted to avoid unnecessary broad-spectrum antibacterial use.
II. Key Pre-treatment Assessment Points
1. Detailed Allergy History Inquiry
(1) Before administration, patients must be asked about any history of allergy to cefepime, other cephalosporins, penicillins, or other beta-lactam agents.
(2) Use is contraindicated in patients with a history of severe hypersensitivity; cross-allergy risk must be given high attention.
2. Baseline Renal Function Assessment
(1) Renal function (calculate eGFR) should be tested before initiating therapy, and the starting dose and dosing interval should be determined based on the results.
(2) Patients with renal impairment (eGFR < 60 mL/min) require immediate dose adjustment to avoid drug accumulation and toxicity.
3. Concomitant Medication Review
(1) If aminoglycosides or potent diuretics (e.g., furosemide) are co-administered, nephrotoxicity risk should be assessed and monitoring intensified.
(2) Review whether the patient is using drugs that may affect coagulation function, as Zaynich may prolong prothrombin time.
4. Identification of Special Physiological States
(1) Experience in pregnant, breastfeeding women, and individuals under 18 years is limited; a full benefit-risk assessment is needed.
(2) Elderly patients, due to natural decline in renal function, require more precise dose adjustments.
III. Key Safety Monitoring Points During Administration
1. Immediate Recognition and Management of Allergic Reactions
(1) During and after infusion, closely observe for signs of allergy such as rash, pruritus, facial/laryngeal edema, and dyspnea.
(2) If a severe allergic reaction occurs, discontinue the drug immediately and provide supportive care; do not continue infusion.
2. Self-Monitoring for Neurotoxic Symptoms
(1) Watch for changes in level of consciousness (including confusion, hallucinations, somnolence, coma), speech comprehension difficulties, muscle twitching, or seizures.
(2) Even after dose adjustment based on renal function, these may still occur, especially in elderly patients or those with severe renal impairment.
3. Vigilance for Diarrhea and Intestinal Infection
(1) If persistent watery stool, bloody stool, or diarrhea with fever and abdominal pain occurs during treatment or within months after discontinuation, be alert for Clostridioides difficile infection.
(2) Do not take antidiarrheal agents on your own; seek medical evaluation promptly.
